Immunome, Inc. (IMNM) has a consensus analyst rating of Buy, based on 10 analysts covering the stock. Of those, 10 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for IMNM is $36.83, representing a +60.8% upside from the current price of $22.9. Price targets range from a low of $32.00 to a high of $40.00.
